Home Sectors Healthcare Stock Analysis: Eli Lilly And Company (NYSE: LLY)

Stock Analysis: Eli Lilly And Company (NYSE: LLY)


Eli Lilly And Company trades as part of the drug manufacturers industry and trades as part of the healthcare sector. The company CEO is David A. Ricks. Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

Previous Intraday Trading Performance:

The LLY stock showed a previous change of -1.67% with an open at 125.15 and a close of 123.06. It reached an intraday high of 125.24 and a low of 123.02.

SeekingAlpha:  Bulletproof Investing Performance Update: Week 72


The stock has a market cap of $119.4b with 970.4m shares outstanding, of which the float is 966.2m shares. Trading volume reached 5,469,802 shares compared to its average volume of 17,464,391 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Eli Lilly And Company shares returned -3.22% and in the past 30 trading days it returned -3.45%. Over three months, it changed 5.67%. In one year it has changed 57.14% and within that year its 52-week high was 132.13 and its 52-week low was 77.09. LLY stock is 59.63% above its 52 Week Low.

Our calculations show a 200 day moving average of 110.34 and a 50 day moving average of 124.82. Currently LLY stock is trading 11.53% above its 200 day moving average.

SeekingAlpha:  Bulletproof Investing Performance Update: Week 72


The last annual fiscal EPS for the company was reported at 3.13 that ended on 31st of December 2018, which according to the previous close, that is a PE of 39.32. Based on 1 analyst estimate, the estimated EPS for the next quarter is 1.35. The TTM EPS is 5.56, which comes to a TTM PE of 22.13.

The dividend per share is currently 2.58, which is a dividend yield of 2.10%. Also, the payout ratio is 46.40%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 137.01, which means it is possibly undervalued and has a margin of safety of 10.18%

Indicators to Watch:

Based on the latest filings, there is 0.40% of insider ownership and 127.80% of institutional ownership. Short-interest is 35,064,784, which is 3.61% of shares outstanding. The short-interest ratio or days-to-cover ratio is 1.11. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 0.31

Business Wire:  Leucadia Has Repurchased 20 Million Shares of Common Stock Since April 10, 2018

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 30.18%, return on assets is 7.27%, profit margin is 10.68%, price-to-sales is 6.44 and price-to-book is 12.15.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 1  :Past Performance Score
 3  :Financial Strength Score
 3  :Future Growth Score
 5  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.